ZOLL, an Asahi Kasei company specializing in medical devices and software solutions, has announced the U.S. release of the next generation LifeVest wearable cardioverter defibrillator. This launch marks the fifth FDA-approved LifeVest WCD, designed to work seamlessly with the newly introduced LifeVest garment, which is noted as the most comfortable version to date. LifeVest has long set the standard in the WCD market by providing highly effective and safe therapy for patients at risk of sudden cardiac death while achieving the highest levels of patient compliance according to published studies and real-world evidence.
Health Technology Insights: NeuraLight Unveils Scientific Leaders Advancing Neurology
Mike Blastick, President of ZOLL Cardiac Management Solutions, stated that the company continues to innovate to give patients reliable protection from sudden cardiac death with a device that fits smoothly into daily life. He emphasized that the newest LifeVest builds on advanced technology and patient-focused design to offer a superior experience outside of the hospital.
Health Technology Insights: FDA Approves NUZOLVENCE, First-in-Class Gonorrhea Drug
The updated LifeVest WCD monitor incorporates design elements shaped by extensive patient feedback and safety testing. The last three generations of LifeVest include response buttons directly on the monitor, enabling conscious patients to delay unnecessary treatment. Data from the SCD-PROTECT study of nearly 20,000 patients showed the inappropriate shock rate is extremely low at 0.5 percent, the lowest among published WCD data. The last two generations also feature a large touchscreen for easy interaction with system messages, eliminating the need for a separate smartphone-style device. LifeVest remains the only WCD that allows patients to interact directly with the system without an extra device.
The next generation LifeVest garment has been engineered for patient comfort and daily usability, supporting a wide range of chest sizes from 26 to 56 inches. It features lightweight fabric inspired by athletic wear, soft plush straps, and flat-lock stitching. Clinical adoption of LifeVest continues to grow as evidence supports the need for sudden cardiac death protection, particularly for newly diagnosed heart failure patients with reduced ejection fraction. The device also includes an AI-enhanced algorithm, introduced in 2018, which continues to minimize false alarms effectively.
LifeVest ranks first in patient compliance with an average use of 23.4 hours per day, based on peer-reviewed publications and real-world data. The SCD-PROTECT study confirmed its safety, showing a 0.5 percent rate of inappropriate shocks, 99.7 percent of patients experienced no skin irritation that required discontinuation, and no deaths from ventricular tachycardia or ventricular fibrillation occurred while wearing LifeVest. Clinical trials and real-world data demonstrate a first shock success rate above 97 percent, and LifeVest is the only WCD with complete conversion of VT/VF in a randomized control trial. With more than 140,000 patients included in clinical studies and over one million lives protected, LifeVest remains the most widely used, studied, and validated wearable defibrillator available.
Health Technology Insights: Acadia Pharma Gets FDA Approval for DAYBUE STIX Oral Solution
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
